A Phase 3, Multi-center, Double-Blind, Active-Controlled, Randomized Study to Evaluate Efficacy and Safety of Zabofloxacin Tablet 400mg and Moxifloxacin Tablet 400mg After Multi-dose Oral Administration in Patients With Acute Bacterial Exacerbation of Chronic Obstructive Pulmonary Disease.

Trial Profile

A Phase 3, Multi-center, Double-Blind, Active-Controlled, Randomized Study to Evaluate Efficacy and Safety of Zabofloxacin Tablet 400mg and Moxifloxacin Tablet 400mg After Multi-dose Oral Administration in Patients With Acute Bacterial Exacerbation of Chronic Obstructive Pulmonary Disease.

Completed
Phase of Trial: Phase III

Latest Information Update: 10 May 2017

At a glance

  • Drugs Zabofloxacin (Primary) ; Moxifloxacin
  • Indications Bacterial infections; Chronic obstructive pulmonary disease
  • Focus Registrational; Therapeutic Use
  • Sponsors Dong Wha Pharmaceutical
  • Most Recent Events

    • 06 Aug 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 16 Jan 2014 Planned End Date changed from 1 Feb 2014 to 21 Apr 2014 as reported by Korean Clinical Trials Register record
    • 15 Jan 2014 Planned End Date changed from 1 Mar 2014 to 1 Feb 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top